JSPR
NASDAQJasper Therapeutics Inc.
Price$0.46-0.02 (-3.51%)
03:00 PM07:45 PM
News · 26 weeks29-57%
2025-12-142026-06-07
Mix1490d
- SEC Filings7(50%)
- Other5(36%)
- Analyst2(14%)
Latest news
25 items- SECJasper Therapeutics Inc. filed SEC Form 8-K: Regulation FD Disclosure, Financial Statements and Exhibits8-K - Jasper Therapeutics, Inc. (0001788028) (Filer)
- PRJasper Therapeutics Announces Exploration of Strategic Alternatives to Maximize Shareholder ValueREDWOOD CITY, Calif., June 01, 2026 (GLOBE NEWSWIRE) -- Jasper Therapeutics, Inc. (NASDAQ:JSPR) (Jasper), a clinical stage biotechnology company focused on development of briquilimab, a novel antibody therapy targeting c-Kit (CD117) to address mast cell driven diseases such as chronic spontaneous urticaria (CSU), chronic inducible urticaria (CIndU) and asthma, today announced that, following an evaluation of current market conditions, its Board of Directors has decided to initiate a comprehensive review of strategic alternatives aimed at maximizing shareholder value. Strategic alternatives being evaluated include, among other options, a sale of assets, licensing of assets, collaborations,
- SECJasper Therapeutics Inc. filed SEC Form 8-K: Leadership Update, Financial Statements and Exhibits8-K - Jasper Therapeutics, Inc. (0001788028) (Filer)
- ANALYSTJasper Therapeutics downgraded by TD CowenTD Cowen downgraded Jasper Therapeutics from Buy to Hold
- SECSEC Form 10-Q filed by Jasper Therapeutics Inc.10-Q - Jasper Therapeutics, Inc. (0001788028) (Filer)
- SECJasper Therapeutics Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits8-K - Jasper Therapeutics, Inc. (0001788028) (Filer)
- PRJasper Therapeutics Reports First Quarter 2026 Financial Results and Provides Corporate UpdateREDWOOD CITY, Calif., May 14, 2026 (GLOBE NEWSWIRE) -- Jasper Therapeutics, Inc. (NASDAQ:JSPR) (Jasper), a clinical stage biotechnology company focused on development of briquilimab, a novel antibody therapy targeting c-Kit (CD117) to address mast cell driven diseases such as chronic spontaneous urticaria (CSU), chronic inducible urticaria (CIndU) and asthma, today reported results for the fiscal quarter ended March 31, 2026 and provided a corporate update. "In recent months, we have continued to advance the briquilimab development program in CSU," said Jeet Mahal, President and Chief Executive Officer of Jasper. "Following our positive clinical data update in January, we have conducted a
- SECAmendment: SEC Form SCHEDULE 13G/A filed by Jasper Therapeutics Inc.SCHEDULE 13G/A - Jasper Therapeutics, Inc. (0001788028) (Subject)
- SECAmendment: SEC Form SCHEDULE 13G/A filed by Jasper Therapeutics Inc.SCHEDULE 13G/A - Jasper Therapeutics, Inc. (0001788028) (Subject)
- SECAmendment: SEC Form 10-K/A filed by Jasper Therapeutics Inc.10-K/A - Jasper Therapeutics, Inc. (0001788028) (Filer)
- SECJasper Therapeutics Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits8-K - Jasper Therapeutics, Inc. (0001788028) (Filer)
- SECSEC Form 10-K filed by Jasper Therapeutics Inc.10-K - Jasper Therapeutics, Inc. (0001788028) (Filer)
- PRJasper Therapeutics Reports Fourth Quarter and Year-End 2025 Financial Results and Provides Corporate UpdateREDWOOD CITY, Calif., March 30, 2026 (GLOBE NEWSWIRE) -- Jasper Therapeutics, Inc. (NASDAQ:JSPR) (Jasper), a clinical stage biotechnology company focused on development of briquilimab, a novel antibody therapy targeting c-Kit (CD117) to address mast cell driven diseases such as chronic spontaneous urticaria (CSU), chronic inducible urticaria (CIndU) and asthma, today reported results for the fiscal quarter and year ended December 31, 2025 and provided a corporate update. "Briquilimab has demonstrated the potential for a compelling and differentiated profile in both CSU and CIndU, along with proof of concept in asthma," said Jeet Mahal, President and Chief Executive Officer of Jasper. "We
- ANALYSTUBS resumed coverage on Jasper Therapeutics with a new price targetUBS resumed coverage of Jasper Therapeutics with a rating of Neutral and set a new price target of $1.50
- SECSEC Form SCHEDULE 13G filed by Jasper Therapeutics Inc.SCHEDULE 13G - Jasper Therapeutics, Inc. (0001788028) (Subject)
- PRJasper Therapeutics to Present at 46th Annual TD Cowen Healthcare ConferenceREDWOOD CITY, Calif., Feb. 24, 2026 (GLOBE NEWSWIRE) -- Jasper Therapeutics, Inc. (NASDAQ:JSPR) (Jasper), a clinical stage biotechnology company focused on development of briquilimab, a novel antibody therapy targeting KIT (CD117) to address mast cell driven diseases such as chronic spontaneous urticaria (CSU), chronic inducible urticaria (CIndU) and asthma, today announced that management will participate at the 46th Annual TD Cowen Healthcare Conference, taking place March 2-4, 2026 in Boston, MA. 46th Annual TD Cowen Healthcare ConferenceConference Dates: March 2-4, 2026Presentation Date/Time: Monday, March 2, 2026; 3:50 PM ESTPresentation Format: Fireside Chat A live webcast of the f
- SECAmendment: SEC Form SCHEDULE 13D/A filed by Jasper Therapeutics Inc.SCHEDULE 13D/A - Jasper Therapeutics, Inc. (0001788028) (Subject)
- SECSEC Form SCHEDULE 13G filed by Jasper Therapeutics Inc.SCHEDULE 13G - Jasper Therapeutics, Inc. (0001788028) (Subject)
- SECSEC Form SCHEDULE 13G filed by Jasper Therapeutics Inc.SCHEDULE 13G - Jasper Therapeutics, Inc. (0001788028) (Subject)
- INSIDERSEC Form 4 filed by CEO and President Mahal Jeetinder Singh4 - Jasper Therapeutics, Inc. (0001788028) (Issuer)
- SECAmendment: SEC Form SCHEDULE 13G/A filed by Jasper Therapeutics Inc.SCHEDULE 13G/A - Jasper Therapeutics, Inc. (0001788028) (Subject)
- ANALYSTRodman & Renshaw initiated coverage on Jasper Therapeutics with a new price targetRodman & Renshaw initiated coverage of Jasper Therapeutics with a rating of Buy and set a new price target of $17.00
- SECJasper Therapeutics Inc. filed SEC Form 8-K: Other Events, Financial Statements and Exhibits8-K - Jasper Therapeutics, Inc. (0001788028) (Filer)
- PRJasper Therapeutics Reports Positive Updated Data from Briquilimab Studies in Chronic Spontaneous Urticaria67% of additional patients (n=6) enrolled in the BEACON study achieved a complete response at 12 weeks with a mean UAS7 reduction of 31 points 75% of CSU participants (n=36) enrolled in the open label extension study achieved a complete response or well controlled disease at 12 weeks With a median duration of follow up of more than 200 days on 63 participants in the open label extension study, KIT related AEs were low in frequency and predominantly low-grade events that resolved while on study BEACON and open label extension data sets are now sufficient to select doses for the Phase 2b study of briquilimab in CSU planned to commence in the second half of 2026 Company to host conference
- SECJasper Therapeutics Inc. filed SEC Form 8-K: Leadership Update, Other Events, Financial Statements and Exhibits8-K - Jasper Therapeutics, Inc. (0001788028) (Filer)
JSPR FAQ
7 questionsWhat does Jasper Therapeutics Inc. do?
Jasper Therapeutics, Inc., a clinical-stage biotechnology company, develops therapeutic agents for hematopoietic stem cell transplantation and gene therapies. The company develops JSP191, a humanized monoclonal antibody for clearing hematopoietic stem cells from bone marrow in patients undergoing a hematopoietic cell transplantation. It also develops Jasper eHSC Platform to overcome key limitations of allogeneic and autologous gene-edited stem cell grafts. The company is based in Redwood City, California.Where does JSPR stock trade?
Jasper Therapeutics Inc. (JSPR) is listed on NASDAQ.What sector and industry is JSPR in?
Jasper Therapeutics Inc. operates in the Health Care sector, Biotechnology: Biological Products (No Diagnostic Substances) industry.When did Jasper Therapeutics Inc. go public?
Jasper Therapeutics Inc. (JSPR) completed its IPO in 2020.What are analysts saying about JSPR?
Jasper Therapeutics Inc. has had 8 recent analyst actions on file. The most recent action was from TD Cowen: Hold on 2026-05-15.What companies are similar to JSPR?
Notable peers in the same industry include AMGN (Amgen Inc.), GILD (Gilead Sciences Inc.), ARGX (argenx SE), RVMD (Revolution Medicines Inc.), BIIB (Biogen Inc.). Compare JSPR side-by-side with any of them on Quantisnow.How can I track JSPR on Quantisnow?
Quantisnow aggregates Jasper Therapeutics Inc.'s SEC filings, analyst ratings, insider transactions, FDA approvals, and press releases the moment they hit the wire (Wall Street's wire, on your screen.). Follow JSPR to receive live email and push alerts on every new disclosure.